Considering the prevalence of nonresponse of IFNα in melanoma cells and tissues [12, 13], uncovering the mechanism of IFN dysfunction may be helpful for improving the therapeutic effect of the IFNα-based approach and improving the efficacy of chemotherapy and immunotherapy for tumor control in patients. This evidence concerns the gene IFNA1 and melanoma.